Corticosteroids for pulmonary sarcoidosis

Area of Science:

• Pulmonology
• Clinical Trials
• Pharmacology

Background:

• Pulmonary sarcoidosis is a common idiopathic inflammatory disease with unpredictable progression.
• Corticosteroids, including oral (OCS) and inhaled (ICS), are frequently used but optimal treatment strategies remain unclear.
• The long-term benefits and side effects of corticosteroid therapy necessitate evidence-based guidelines.

Purpose of the Study:

• To systematically review randomized controlled trials (RCTs) evaluating the efficacy of corticosteroids in treating pulmonary sarcoidosis.
• To assess the impact of oral and inhaled corticosteroids on radiological, functional, and symptomatic outcomes.

Main Methods:

• Comprehensive literature search of MEDLINE, EMBASE, and CENTRAL databases up to May 2004.
• Inclusion criteria: RCTs or controlled clinical trials in adults with histologically confirmed pulmonary sarcoidosis treated with OCS or ICS.
• Data extraction and quality assessment by two independent reviewers; primary outcome: chest X-ray (CXR) changes.

Main Results:

• Twelve RCTs involving 1051 participants met the criteria; OCS doses ranged from 4-40 mg/day prednisolone.
• Oral corticosteroids showed a modest improvement in CXR over 3-24 months (RR 1.46), but lung function benefits were not significant.
• Insufficient data precluded meaningful analysis for ICS; limited evidence suggested symptom improvement in one study.

Conclusions:

• Oral steroids appear to improve CXR, symptoms, and spirometry in pulmonary sarcoidosis over 3-24 months.
• Evidence for sustained lung function improvement or long-term disease modification by corticosteroids is limited.
• Corticosteroids may benefit patients with Stage 2 and 3 disease exhibiting moderate to severe symptoms or CXR changes.